Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

SBI-115 is an antagonist of G protein-coupled bile acid receptor 1 (GPBAR1), also known as TGR5.1 It inhibits taurolithocholic acid-induced increases in cAMP levels in, and proliferation of, cholangiocytes isolated from patients with autosomal dominant polycystic kidney disease when used at concentrations of 100 and 200 µM. SBI-115 (10 µM) decreases the viability of, and protein levels of GPBAR1 in, PANC-1 pancreatic cancer cells.2 In vivo, SBI-115 (80 mg/kg) prevents B. pseudocatenulatum-induced decreases in serum levels of IFN-γ and IL-17A in a mouse model of collagen-induced arthritis.3
WARNING This product is not for human or veterinary use.
1. TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling. Hepatology 66(4), 1197-1218 (2017).
2. Investigation of the potential role of TGR5 in pancreatic cancer by a comprehensive molecular experiments and the liquid chromatography mass spectrometry (LC–MS) based metabolomics. Discov. Oncol. 13(46), (2022).
3. Bifidobacterium pseudocatenulatum-